Detalles de la búsqueda
1.
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
Diabetes Obes Metab
; 25(1): 261-271, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36097728
2.
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Am J Kidney Dis
; 79(6): 796-806, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34752913
3.
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Eur Heart J
; 42(6): 700-710, 2021 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33351892
4.
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.
Cost Eff Resour Alloc
; 19(1): 46, 2021 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34348729
5.
Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure.
J Am Soc Nephrol
; 31(7): 1594-1601, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32487562
6.
Comparison of Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Multicriteria Decision Analysis.
Value Health
; 20(10): 1394-1402, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29241899
7.
Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.
Diabetes Ther
; 13(11-12): 1891-1906, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36315384
8.
Healthcare resource utilization in patients treated with empagliflozin in East Asia.
J Diabetes Investig
; 13(5): 810-821, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34859609
9.
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
J Comp Eff Res
; 10(6): 469-480, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33576249
10.
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
BMJ Open Diabetes Res Care
; 9(1)2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33941549
11.
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
J Am Heart Assoc
; 10(11): e019356, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34032121
12.
Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
J Comp Eff Res
; 9(11): 781-794, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32573253
13.
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
Diabetes Ther
; 11(9): 2041-2055, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700188
14.
Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.
PLoS One
; 15(3): e0229621, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130249
15.
Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
ESC Heart Fail
; 7(6): 3910-3918, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32909680
16.
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.
Diabetes Ther
; 10(6): 2153-2167, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31602601
17.
Correction to: Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons.
Diabetes Ther
; 10(1): 325-326, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30519858
18.
Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
Eur J Heart Fail
; 21(7): 932-942, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31218819
19.
Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Clin Ther
; 41(10): 2021-2040.e11, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31561882
20.
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.
Curr Med Res Opin
; 34(1): 55-63, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28862479